Literature DB >> 32242993

Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk.

Alpo Vuorio1,2, Gerald F Watts3,4, Petri T Kovanen5.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32242993     DOI： 10.1111/joim.13070

Source DB:  PubMed          Journal:  J Intern Med        ISSN： 0954-6820            Impact factor:   8.989


× No keyword cloud information.
  15 in total

Review 1.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

2.  COVID-19 Knowledge, Attitudes, and Prevention Practices Among People with Hypertension and Diabetes Mellitus Attending Public Health Facilities in Ambo, Ethiopia.

Authors:  Getu Melesie Taye; Lemma Bose; Tamirat Bekele Beressa; Gosaye Mekonnen Tefera; Biruk Mosisa; Hunduma Dinsa; Adamu Birhanu; Gurmu Umeta
Journal:  Infect Drug Resist       Date:  2020-11-23       Impact factor: 4.003

Review 3.  Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?

Authors:  Gelsomina Mansueto; Massimo Niola; Claudio Napoli
Journal:  Pathol Res Pract       Date:  2020-06-26       Impact factor: 3.250

4.  Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.

Authors:  Kalpana Thapa Bajgain; Sujan Badal; Bishnu B Bajgain; Maria J Santana
Journal:  Am J Infect Control       Date:  2020-07-10       Impact factor: 2.918

5.  Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic.

Authors:  Maciej Banach; Peter E Penson; Zlatko Fras; Michal Vrablik; Daniel Pella; Željko Reiner; Seyed Mohammad Nabavi; Amirhossein Sahebkar; Meral Kayikcioglu; Magdalena Daccord
Journal:  Pharmacol Res       Date:  2020-05-07       Impact factor: 7.658

Review 6.  May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

Authors:  Roberto Scicali; Antonino Di Pino; Salvatore Piro; Agata M Rabuazzo; Francesco Purrello
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-05-13       Impact factor: 4.222

7.  Lipoprotein(a) and SARS-CoV-2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events.

Authors:  Silvia Di Maio; Claudia Lamina; Stefan Coassin; Lukas Forer; Reinhard Würzner; Sebastian Schönherr; Florian Kronenberg
Journal:  J Intern Med       Date:  2021-10-29       Impact factor: 13.068

8.  Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction.

Authors:  Petri T Kovanen; Frederick Raal; Alpo Vuorio
Journal:  Am J Prev Cardiol       Date:  2021-07-20

Review 9.  ACE2 enhance viral infection or viral infection aggravate the underlying diseases.

Authors:  Shaolei Teng; Qiyi Tang
Journal:  Comput Struct Biotechnol J       Date:  2020-08-06       Impact factor: 7.271

10.  Statins and the COVID-19 main protease: in silico evidence on direct interaction.

Authors:  Željko Reiner; Mahdi Hatamipour; Maciej Banach; Matteo Pirro; Khalid Al-Rasadi; Tannaz Jamialahmadi; Dina Radenkovic; Fabrizio Montecucco; Amirhossein Sahebkar
Journal:  Arch Med Sci       Date:  2020-04-25       Impact factor: 3.318
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.